Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 0 Master Protocol Using the CIVO Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients With Solid Tumors

Next Previous
Trial Profile

A Phase 0 Master Protocol Using the CIVO Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients With Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 25 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Rilvegostomig (Primary) ; Sabestomig (Primary) ; Volrustomig (Primary)
  • Indications Advanced breast cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Presage Biosciences

Most Recent Events

  • 22 May 2026 Status changed to active, no longer recruiting.
  • 15 Apr 2024 The protocol has been amended to add 2 more sub-studies to this parent study and melanoma, breast cancer and lymphoma to indications.
  • 30 Nov 2023 According to a Presage Biosciences media release, the data from this trial was presented at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top